Related Experiment Video
Updated: May 4, 2026
09:01
Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
Published on: June 5, 2010
13.4K
[Biologic therapy in idiopathic inflammatory myopathy]
Albert Selva-O'Callaghan1, Manel Ramos Casals2, Josep M Grau Junyent3
1Servicio de Medicina Interna, Hospital General Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España.
Medicina Clinica
|January 8, 2014
Summary
Biological therapies are not yet a recommended treatment for idiopathic inflammatory myopathies, including dermatomyositis and polymyositis. However, they may be considered for refractory cases due to limited effective options.
Area of Science:
- Rheumatology and Immunology
- Clinical Therapeutics
Context:
- Idiopathic inflammatory myopathies (IIMs) encompass dermatomyositis, polymyositis, and inclusion body myositis.
- These rare and heterogeneous autoimmune diseases present significant treatment challenges.
- Limited effective therapeutic options exist, particularly for refractory disease presentations.
Purpose:
- To review and analyze evidence-based knowledge on biological therapies for IIMs.
- To evaluate the methodological quality of published studies, focusing on randomized controlled trials.
- To address limitations in research due to disease rarity and heterogeneity.
Summary:
- Current evidence does not support biological therapies as a standard recommendation for IIMs.
- Analysis of high-quality studies reveals insufficient data to establish efficacy and safety.
- Biologicals may be considered as an option for refractory IIM cases, given treatment limitations.
Impact:
- Highlights the need for rigorous research to define the role of biologics in IIM management.
- Informs clinical decision-making for challenging IIM cases.
- Guides future research directions in autoimmune myopathies.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:27Myocarditis II: Clinical Features and Diagnostic Tests
493
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
493
01:26Inflammatory Bowel Disease I: Introduction
42
Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows...
42
01:25Inflammatory Bowel Disease III: Crohn's Disease
35
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
35